Maraviroc - CAS 376348-65-1
Catalog number: B0084-067502
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
Selective CCR5 antagonist
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-067502 50 mg $199 In stock
Bulk Inquiry
Brife Description:
Selective CCR5 antagonist
White to Off-White Solid
Maraviroc; Selzentry; Celsentri; UK-427857; UK-427,857; Pfizer Brand of maraviroc; Selzentry; UK-427,857; UK-427857; 4,4-Difluoro-N-[(1S)-3-[(3-exo)-3-[3-methyl-5-(1-methylethyl-d6)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl]cyclohexanecarboxamide; UK 427857-d6;
Soluble to 75 mM in DMSO and to 100 mM in ethanol
Store at +4°C
Quality Standard:
Shelf Life:
24 months.
Melting Point:
Canonical SMILES:
1.Maraviroc, as a switch option, in HIV-1 infected individuals with stable, well-controlled HIV replication and R5-tropic virus on their first N(t)RTI+PI/r regimen. Week 48 results of the randomised, multicentre MARaviroc switCH study (MARCH).
Pett SL1, Amin J2, Horban A3, Andrade-Villanueva J4, Losso M5, Porteiro N6, Sierra Madero J7, Belloso W8, Tu E2, Silk D2, Kelleher A9, Harrigan R10, Clark A11, Sugiura W12, Wolff M13, Gill J14, Gatell J15, Fisher M16, Clarke A16, Ruxrungtham K17, Prazuck Clin Infect Dis. 2016 Apr 5. pii: ciw207. [Epub ahead of print]
BACKGROUND:  Alternative combination antiretroviral therapies in virologically suppressed HIV-infected patients experiencing side-effects and/or at ongoing risk of important co-morbidities from current therapy are needed. Maraviroc(MVC), a chemokine receptor-5(CCR5) antagonist, is a potential alternative component of therapy in those with R5-tropic virus.
2.Coaxially electrospun fiber-based microbicides facilitate broadly tunable release of maraviroc.
Ball C1, Chou SF1, Jiang Y1, Woodrow KA2. Mater Sci Eng C Mater Biol Appl. 2016 Jun 1;63:117-24. doi: 10.1016/j.msec.2016.02.018. Epub 2016 Feb 4.
Electrospun fibers show potential as a topical delivery system for vaginal microbicides. Previous reports have demonstrated delivery of anti-HIV and anti-STI (sexually transmitted infection) agents from fibers formulated using hydrophilic, hydrophobic, or pH-responsive polymers that result in rapid, prolonged, or stimuli-responsive release, respectively. However, coaxial electrospun fibers have yet to be evaluated as a highly tunable microbicide delivery vehicle. In this research, we explored the opportunities and limitations of a model coaxial electrospun fiber system to provide broad and tunable release rates for the HIV entry inhibitor maraviroc. Specifically, we prepared ethyl cellulose (EC)-shell and polyvinylpyrrolidone (PVP)-core fibers that were capable of releasing actives over a range of hours to several days. We further demonstrated simple and effective methods for combining core-shell fibers with rapid-release formulations to provide combined instantaneous and sustained maraviroc release.
3.The CD4/CD8 ratio is inversely associated with cIMT progression in HIV infected patients on antiretroviral treatment.
Bernal Morell E1, Serrano Cabeza J2, Muñoz A3, Marín I4, Masia M5, Gutierrez F6, Cano A7. AIDS Res Hum Retroviruses. 2016 Mar 22. [Epub ahead of print]
Inversion of the CD4/CD8 ratio (< 1) has been identified as a surrogate marker of immunosenescence, and an independent predictor of AIDS events in HIV infected patients and mortality in the general population. We aimed to assess the association between the CD4/CD8 ratio and carotid intima-media thickness (cIMT) progression in treated HIV-infected patients as a marker of coronary heart disease. A longitudinal study was conducted during three years in 96 virally suppressed HIV infected patients receiving antiretroviral treatment (ART). We analyzed the associations between the CD4/CD8 ratio, cardiovascular risk factors and antiretroviral treatment (ARV), and progression of subclinical atherosclerosis assessed using carotid cIMT at baseline and after three years. Finally, ninety-six patients completed the study. Seventy six (79.1%) patients were male, aged 44±10 years, 39 (40.6%) were on treatment with protease inhibitors; 49 (51.04%) with non-nucleoside reverse transcriptase inhibitors (NNRTI), 6 (6.
4.Maraviroc reduces neuropathic pain through polarization of microglia and astroglia - Evidence from in vivo and in vitro studies.
Piotrowska A1, Kwiatkowski K1, Rojewska E1, Makuch W1, Mika J2. Neuropharmacology. 2016 Apr 23. pii: S0028-3908(16)30164-2. doi: 10.1016/j.neuropharm.2016.04.024. [Epub ahead of print]
Recent studies suggest that CCR5 and its ligands are important regulators for the development of neuropathic pain and that their modulation can have some beneficial properties. Therefore, the aim of our study was to investigate the influence of maraviroc (MVC, a CCR5 antagonist) on glial polarization markers and intracellular signaling pathways in the spinal cord 7 days after chronic constriction injury (CCI) to the sciatic nerve and in primary glial cultures after LPS stimulation. Our results demonstrated that chronic intrathecal administration of MVC diminished neuropathic pain symptoms and nociceptive threshold ∼60 min after drug administration on days 3 and 7 post-CCI. MVC downregulated the levels of phosphorylated p38 MAPK, ERK1/2 and NF-κB proteins in the spinal cord and upregulated STAT3 in the dorsal root ganglia (DRG). Additionally, using Western blot analysis, we demonstrated that MVC effectively diminished "classical" activation markers: IL-1β, IL-18, IL-6 and NOS2 in the spinal cord.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related CCR Products

CAS 150378-17-9 Indinavir

(CAS: 150378-17-9)

Indinavir is a member of the novel hydroxyaminopentane amide class of HIV-1 protease inhibitors. Indinavir is used as an antiviral.

CAS 566203-88-1 AZD 2098

AZD 2098
(CAS: 566203-88-1)

AZD 2098 is a potent and selective CCR4 receptor antagonist (pIC50 = 7.8) used for the treatment of allergic rhinitis. CCR4 is a molecule that can drive the imm...

CAS 150608-41-6 CGP 57813

CGP 57813
(CAS: 150608-41-6)

CGP 57813 has been found to be a HIV-1 protease inhibitor that has been once developed by Novartis.

CAS 288262-96-4 BX471 hydrochloride

BX471 hydrochloride
(CAS: 288262-96-4)

Potent, selective non-peptide CCR1 antagonist (Ki = 1 nM for human CCR1)

(CAS: 698394-73-9)

Highly potent antagonist of CCR9

CAS 217645-70-0 BX 471

BX 471
(CAS: 217645-70-0)

Selective CCR1 antagonist

CAS 1262238-11-8 INCB3344

(CAS: 1262238-11-8)

INCB3344 is a potent CCR2 antagonist with IC50 of 5.1 nM and 9.5 nM for hCCR2 and mCCR2, respectively.

CAS 1226894-87-6 YJC-10592

(CAS: 1226894-87-6)

YJC-10592 is a CC chemokine receptor 2 (CCR2) antagonist (IC50 value 1.12 μM).

Chemical Structure

CAS 376348-65-1 Maraviroc

Quick Inquiry

Verification code

Featured Items